ES2069715T3 - Secuencia de oligonucleotidos antisentido, anti-arn mensajero del tnf alfa, procedimiento de preparacion, aplicacion como medicamentos y composiciones farmaceuticas. - Google Patents

Secuencia de oligonucleotidos antisentido, anti-arn mensajero del tnf alfa, procedimiento de preparacion, aplicacion como medicamentos y composiciones farmaceuticas.

Info

Publication number
ES2069715T3
ES2069715T3 ES90402329T ES90402329T ES2069715T3 ES 2069715 T3 ES2069715 T3 ES 2069715T3 ES 90402329 T ES90402329 T ES 90402329T ES 90402329 T ES90402329 T ES 90402329T ES 2069715 T3 ES2069715 T3 ES 2069715T3
Authority
ES
Spain
Prior art keywords
sequence
application
pharmaceutical compositions
messenger rna
preparation procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90402329T
Other languages
English (en)
Inventor
Abdel Karim Braham
Pierre Smets
Rene Zalisz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Application granted granted Critical
Publication of ES2069715T3 publication Critical patent/ES2069715T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02K—DYNAMO-ELECTRIC MACHINES
    • H02K2203/00—Specific aspects not provided for in the other groups of this subclass relating to the windings
    • H02K2203/03—Machines characterised by the wiring boards, i.e. printed circuit boards or similar structures for connecting the winding terminations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Thin Magnetic Films (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)

Abstract

LA SOLICITUD SE REFIERE A UNA SECUENCIA DE OLIGONUCLEOTIDOS ANTISENTIDO, ANTI-ARN MENSAJERO DEL TNF ALFA, DE FORMULA (I), EN LA QUE F ES HIDROGENO O UNA SECUENCIA DE 1 A 17 OLIGONUCLEOTIDOS EN FORMA LIBRE, ALCOHILADA, SULFURADA O DE DERIVADOS DE LA POLI L-LISINA, PROCEDIMIENTO DE PREPARACION, APLICACION COMO MEDICAMENTO Y COMPOSICIONES FARMACEUTICAS QUE CONTIENEN ESTA NUEVA SECUENCIA.
ES90402329T 1989-08-23 1990-08-22 Secuencia de oligonucleotidos antisentido, anti-arn mensajero del tnf alfa, procedimiento de preparacion, aplicacion como medicamentos y composiciones farmaceuticas. Expired - Lifetime ES2069715T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8911171A FR2651130B1 (fr) 1989-08-23 1989-08-23 Sequence d'oligonucleotides anti-sens, anti-arn message du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques.

Publications (1)

Publication Number Publication Date
ES2069715T3 true ES2069715T3 (es) 1995-05-16

Family

ID=9384878

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90402329T Expired - Lifetime ES2069715T3 (es) 1989-08-23 1990-08-22 Secuencia de oligonucleotidos antisentido, anti-arn mensajero del tnf alfa, procedimiento de preparacion, aplicacion como medicamentos y composiciones farmaceuticas.

Country Status (19)

Country Link
US (1) US5705389A (es)
EP (1) EP0414607B1 (es)
JP (1) JPH0391485A (es)
KR (1) KR0151153B1 (es)
CN (1) CN1028760C (es)
AT (1) ATE120201T1 (es)
AU (1) AU642423B2 (es)
CA (1) CA2023899C (es)
DE (1) DE69017983T2 (es)
DK (1) DK0414607T3 (es)
ES (1) ES2069715T3 (es)
FR (1) FR2651130B1 (es)
GR (1) GR3015527T3 (es)
HU (1) HU215242B (es)
IE (1) IE68592B1 (es)
IL (1) IL95342A (es)
PT (1) PT95067B (es)
RU (1) RU2066325C1 (es)
ZA (1) ZA906675B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1250722B (it) * 1991-07-30 1995-04-21 Univ Degli Studi Milano Oligonucleotidi antisenso
TW323284B (es) * 1992-03-23 1997-12-21 Novartis Ag
AU6001094A (en) * 1993-02-03 1994-08-29 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
AU1249299A (en) * 1997-11-25 1999-06-15 Brax Genomics Limited Chimeric antisense oligonucleotides against tnf-alpha and their uses
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US20040006036A1 (en) * 2000-04-12 2004-01-08 Gmr, A Delaware Corporation Silencing transcription by methylation
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
AR040603A1 (es) * 2002-07-19 2005-04-13 Abbott Lab S A El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos
EP1807111A4 (en) * 2004-10-08 2009-05-27 Abbott Biotech Ltd SYNCYTIAL RESPIRATORY VIRUS INFECTION (RSV)
AU2006246721B2 (en) 2005-05-16 2012-12-13 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
CN101235064B (zh) * 2008-02-27 2011-08-10 东南大学 可脱保护的硫代核苷酸单体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0090789A1 (en) * 1982-03-26 1983-10-05 Monsanto Company Chemical DNA synthesis
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
FR2584090B1 (fr) 1985-06-27 1987-08-28 Roussel Uclaf Nouveaux supports, leur preparation et les intermediaires obtenus, leur application a la synthese d'oligonucleotides et les nouveaux nucleosides et oligonucleotides relies aux supports ainsi obtenus
WO1988006625A2 (en) * 1987-02-26 1988-09-07 Cetus Corporation Arginine-depleted human tumor necrosis factor
ATE137806T1 (de) * 1988-07-05 1996-05-15 Baylor College Medicine Verfahren zur identifizierung von bakterien

Also Published As

Publication number Publication date
CN1049668A (zh) 1991-03-06
KR910004198A (ko) 1991-03-28
EP0414607B1 (fr) 1995-03-22
CN1028760C (zh) 1995-06-07
IE903036A1 (en) 1991-02-27
EP0414607A2 (fr) 1991-02-27
CA2023899A1 (fr) 1991-02-24
FR2651130A1 (fr) 1991-03-01
DE69017983T2 (de) 1995-09-28
DK0414607T3 (da) 1995-06-06
ATE120201T1 (de) 1995-04-15
GR3015527T3 (en) 1995-06-30
IE68592B1 (en) 1996-06-26
PT95067A (pt) 1991-04-18
JPH0391485A (ja) 1991-04-17
PT95067B (pt) 1997-05-28
US5705389A (en) 1998-01-06
HU905302D0 (en) 1991-02-28
IL95342A0 (en) 1991-06-30
HU215242B (hu) 1998-11-30
AU642423B2 (en) 1993-10-21
ZA906675B (en) 1991-10-30
HUT56113A (en) 1991-07-29
RU2066325C1 (ru) 1996-09-10
CA2023899C (fr) 2002-05-14
IL95342A (en) 1995-01-24
EP0414607A3 (en) 1991-04-03
KR0151153B1 (ko) 1998-08-17
DE69017983D1 (de) 1995-04-27
AU6119090A (en) 1991-02-28
FR2651130B1 (fr) 1991-12-13

Similar Documents

Publication Publication Date Title
ES2069715T3 (es) Secuencia de oligonucleotidos antisentido, anti-arn mensajero del tnf alfa, procedimiento de preparacion, aplicacion como medicamentos y composiciones farmaceuticas.
BR0113643A (pt) Compostos de guanidinobenzamidas como agonistas de mc4-r e seus usos
EA200300081A1 (ru) Гидрогель-управляемая лекарственная форма
ATE67505T1 (de) Tetrapyrrolverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
AR020051A1 (es) Procedimiento de uso y uso de una combinacion de un anticuerpo anti-erbb2 y un agente quimicoterapeutico distinto de un derivado de antraciclina para la manufactura de un medicamento util para el tratamiento de cancer
AR012614A1 (es) Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento
BR9908219A (pt) Pró-perfumes cìclos tendo taxas de liberação de matéria-prima de álcool com fragrância modificável
DK0799209T3 (da) Sulfonamider
NZ251320A (en) Bis-aromatic alpha,beta-unsaturated ketones, preparation and use in pharmaceutical compositions
EP0288163A3 (en) Oligodeoxynucleotides as inhibitors of the replication of retroviruses and the expression of oncogenes
OA07419A (fr) Activateur de plamimogène de tissu humain, son procédé de production et composition pharmaceutique le contenant.
EG18379A (en) Novel pharmacological compounds
ES2062073T3 (es) Composiciones de tinta que contiene una mezcla de un poliester, un polimero acrilico y un polimero vinilico.
ES2033446T5 (es) Nuevas composiciones depilatorias.
KR910009242A (ko) 치근막 질환 치료용 서방성 조성물
ES2159403T3 (es) Poliuretanos termoplasticos que contienen principios activos.
DE59407457D1 (de) Blockierung der anlagerung von keimen an menschliche zellen
NZ230155A (en) N-2,3-butadienyl-n"-substituted-triamindalkanes and alkenes, and pharmaceutical compositions
ES2129893T3 (es) Dinucleosido-5',5'-pirofosfatos.
ES2072975T3 (es) Mezcla de esterilizante y metodo de esterilizacion.
ES2036419T3 (es) Producto transparente para la limpieza del cabello y del cuerpo.
MX9307203A (es) COMPUESTOS ESTEROIDALES DE ACIL-3-CARBOXI-3,5-DIENO-17Ó Y 17ß -SUBSTITUIDOS.
MX9303952A (es) Barra limpiadora para acondicionar la piel o el cabello.
ATE53004T1 (de) Pharmazeutische zusammensetzungen mit inhalt von 5-phenyl-1,3-dioxoalkenylverbindungen.
MX174093B (es) 1,1-DIOXIDOS DE 3,4-DIHIDRO-2-ALQUIL-3-OXO-N-ARIL-2H[1] BENZOTIENO[3,2-e]-1,2-TIAZINO-4-CARBOXIAMIDA

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 414607

Country of ref document: ES